Sinopharm Group CoSHTDF -2.67%78 PB Ratio is 0.60 as of Jun. 25, 2026, which is 39% below its 10-year median of 0.98. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 112 Medical Distribution companies, Sinopharm Group Co ranks better than 88.39% on this metric.
Sinopharm Group Co Ltd stock PB Ratio (=0.53) is close to 10-year low of 0.52.
The historical rank and industry rank for Sinopharm Group Co's PB Ratio or its related term are showing as below:
SHTDF'
s PB Ratio Range Over the Past 10 Years
Min: 0.52 Med: 0.98 Max: 3.21
Current: 0.53
During the past 13 years, Sinopharm Group Co's highest PB Ratio was 3.21. The lowest was 0.52. And the median was 0.98.
SHTDF's PB Ratio is ranked better than 88.39% of 112
companies
in the Medical Distribution industry
Industry Median: 1.075
vs SHTDF: 0.53
During the past 12 months, Sinopharm Group Co's average Book Value Per Share Growth Rate was 10.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sinopharm Group Co was 77.30% per year. The lowest was 3.60% per year. And the median was 11.30% per year.
Back to Basics: PB Ratio
Sinopharm Group Co (OTCPK:SHTDF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sinopharm Group Co PB Ratio Related Terms
Sinopharm Group Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sinopharm Group Co (SHTDF) has a PB Ratio of 0.60 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinopharm Group Co and its competitors. This is 39% below median its historical median of 0.98. Over the past decade, Sinopharm Group Co's PB Ratio has ranged from 0.52 to 3.21. According to the industry distribution chart, Sinopharm Group Co ranks #13 out of 112 companies in the Medical Distribution industry, placing it in the top 11.6%.
Is Sinopharm Group Co's PB Ratio too high?
Sinopharm Group Co's current PB Ratio of 0.60 is 39% below median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 3.21. The Medical Distribution industry median PB Ratio is 1.08. Sinopharm Group Co's value of 0.60 is 44.2% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #13 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #13 out of 112 companies for PB Ratio. This places Sinopharm Group Co in the top 12% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.08. Sinopharm Group Co's value of 0.60 is 44.2% below this benchmark. Historically, Sinopharm Group Co's own PB Ratio has ranged from 0.52 to 3.21 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 1.08, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.08, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current PB Ratio of 0.60 is 44.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current PB Ratio is 0.60, which is 39% below median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current PB Ratio is 0.60, which is 39% below median its 10-year median of 0.98 and 44.2% below the Medical Distribution industry median of 1.08. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current PB Ratio is 0.60 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
PB Ratio: 0.60 (39% below median its 10-year median of 0.98)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 44.2% below the Medical Distribution median (#13 of 112)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
